Arbor Biotechnologies Announces The Appointment Of Mikael Dolsten, M.D., Ph.D., To Its Board Of Directors To Strengthen Strategic Leadership

Arbor Biotechnologies has announced the appointment of Dr. Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dr. Dolsten brings decades of leadership experience in the biopharmaceutical industry, most notably from his 16-year tenure at Pfizer Inc., where he served as Chief Scientific Officer and President of Worldwide Research, Development, and Medical. In that role, he led the company’s global R&D strategy and was instrumental in advancing a broad portfolio of therapeutics, including gene therapies, biologics, small molecules, and vaccines. He also played a pivotal role in Pfizer’s scientific response to the COVID-19 pandemic.

Dr. Dolsten is widely recognized as a physician-scientist with a strong track record of driving innovation across major pharmaceutical companies, having previously held leadership roles at Boehringer Ingelheim, AstraZeneca, and Wyeth. Over the course of his career, he has contributed to corporate deals valued at over $100 billion. In addition to his new role at Arbor Biotechnologies, Dr. Dolsten serves on the boards of Agilent Technologies and Rocket Pharmaceuticals. He also advises several leading firms and investment groups, including Blackstone Life Sciences, GV (formerly Google Ventures), Bain & Company, and Formation Bio. His involvement spans multiple private biotech companies, such as Orbis Medicine, ImmuneAI, FairJourney Biologics, Orogen Therapeutics, Quarry Thera, and ChAI Discovery.

Paul Meister, Chairman of the Board of Arbor Biotechnologies, mentioned, “Mikael’s experience leading world-class R&D organizations and guiding companies through periods of scientific and operational inflection will be a tremendous asset to Arbor. We are excited to welcome him and look forward to his insights as the company progresses the development of its differentiated portfolio of gene editing therapeutics.”

Dr. Dolsten stated, “I am thrilled to join Arbor’s Board and support the team in realizing the full potential of their next-generation gene editing platform. Arbor’s deep discovery capabilities, pipeline of differentiated in vivo therapeutics, and mission to address genetic diseases at their root cause make it one of the most exciting companies in this space.”

Dr. Dolsten is a Visiting Professor at Lund University in Sweden and a member of the Royal Swedish Academy of Engineering Sciences. He has also provided public health and pandemic preparedness guidance to leadership in both the United States and the United Kingdom. His appointment adds deep scientific and strategic expertise to Arbor’s Board as the company continues to advance its next-generation genetic medicine programs.